2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
August 18, 2020
Video
David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.
August 17, 2020
Article
Guru P. Sonpavde, MD, discusses several trials in the field of first-line metastatic urothelial cancer that are testing combinations with gemcitabine/platinum-based therapy followed by maintenance avelumab.
August 14, 2020
Video
Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.
August 13, 2020
Video
Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.
August 12, 2020
Article
Paul L. Nguyen, MD, discusses the role of radiation in high-risk prostate cancer and ongoing research efforts in the space.
August 10, 2020
Video
Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.
August 06, 2020
Article
Praful K. Ravi, MD, discusses the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates and how they dramatically evolved the metastatic urothelial cancer treatment paradigm.
August 05, 2020
Article
Savolitinib demonstrated encouraging efficacy and an improved safety profile over sunitinib in patients with MET-driven papillary renal cell carcinoma.
August 03, 2020
Video
Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.
June 24, 2020
Article
Caron Jacobson, MD, discusses the initial ZUMA-5 findings and the next steps with axicabtagene ciloleucel in follicular lymphoma and marginal zone lymphoma.
June 23, 2020
Video
Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.
June 11, 2020
Video
Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.
June 10, 2020
Video
Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.
June 10, 2020
Video
Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.
June 05, 2020
Article
Mark M. Awad, MD, PhD, discusses the findings from the study, the importance of identifying patients with METex14 mutations, and the importance of understanding acquired resistance in NSCLC.
June 05, 2020
Video
Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.
June 04, 2020
Article
Immunoglobulin light chain amyloidosis is the most common form of systemic amyloidosis and is characterized by rapidly progressive organ failure and eventually patient demise, if not promptly recognized and treated.
June 03, 2020
Video
Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.
June 02, 2020
Video
Corey S. Cutler, MD, MPH, FRCPC, discusses remaining challenges in graft-versus-host disease.
May 12, 2020
Article
Toni K. Choueiri, MD, discusses the findings from the phase 1/2 trial, the clinical implications of targeting HIF-2α in kidney cancer, and the potential utility of MK-6482 in clear cell RCC.